Medicare GLP-1 Bridge Program: Affordable Access for Beneficiaries
Beginning in July, selected Medicare beneficiaries will have the opportunity to access GLP-1 medications through a fixed monthly payment. This initiative is part of a temporary program scheduled to last eighteen months, concluding at the end of 2027.
The Medicare GLP-1 Bridge program, described by the Centers for Medicare and Medicaid Services (CMS) as a "time-limited demonstration," will run from July 1, 2026, to December 31, 2027. Announced in December, this program allows Medicare Part D enrollees to obtain GLP-1 medications for a $50 monthly copayment, focusing primarily on weight management for beneficiaries.
This initiative aims to assist Medicare users who lack a medical rationale under Part D for GLP-1s, as Medicare is currently prohibited from covering medications solely for weight loss. The Obesity Care Advocacy Network (OCAN) and others have applauded the program's potential to address obesity.
Despite widespread support, questions about the program's administration and financial implications remain. Bob Herman from Stat News noted that CMS has not responded to inquiries regarding program costs. Similarly, The Hill sought insights from the Department of Health and Human Services concerning financing details.
Participants won't need additional paperwork, requiring only a prescription from their healthcare provider. Providers must submit a prior authorization request for GLP-1 medications like Wegovy, Zepbound, and Foundayo. If patients switch medications, a new prior authorization request will be necessary.
Pharmacists will direct prescriptions to the program's centralized processor, known as the Bridge PCN. The agency will not manage prospective prior authorizations, clarified Aurelia Chaudhury with CMS's Cell and Gene Therapy Access Model. Patients must not have Type 2 diabetes, severe obstructive sleep apnea, or MASH fatty liver disease, with claims set to begin processing on July 1.
Health insurance specialist Kelly Strachan stated that the Bridge program tests the effectiveness of accessing GLP-1 medications at a negotiated CMS price to enhance outcomes and reduce long-term Medicare spending. The $50 copay will not count towards deductibles or maximum out-of-pocket costs.
Catherine Varney of the Obesity Medicine Association emphasized the benefits for those at significant risk of obesity-related illnesses. Eligibility includes enrolling in certain Medicare Advantage plans with a BMI of at least 27 with a relevant diagnosis or a BMI of 35 or greater without an additional diagnosis. Industry experts caution about potential misuse, noting increased involvement from telehealth and similar schemes due to this program.